- Home
- FHTX vs MLP Comparison
FHTX vs MLP Comparison
Compare FHTX & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- MLP
- Stock Information
- Founded
- FHTX 2015
- MLP 1909
- Country
- FHTX United States
- MLP United States
- Employees
- FHTX N/A
- MLP N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- MLP Real Estate
- Sector
- FHTX Health Care
- MLP Finance
- Exchange
- FHTX Nasdaq
- MLP Nasdaq
- Market Cap
- FHTX 513.7M
- MLP 512.1M
- IPO Year
- FHTX 2020
- MLP 1972
- Fundamental
- Price
- FHTX $9.04
- MLP $24.75
- Analyst Decision
- FHTX Strong Buy
- MLP
- Analyst Count
- FHTX 5
- MLP 0
- Target Price
- FHTX $16.00
- MLP N/A
- AVG Volume (30 Days)
- FHTX 123.1K
- MLP 16.1K
- Earning Date
- FHTX 11-04-2024
- MLP 11-15-2024
- Dividend Yield
- FHTX N/A
- MLP N/A
- EPS Growth
- FHTX N/A
- MLP N/A
- EPS
- FHTX N/A
- MLP N/A
- Revenue
- FHTX $25,515,000.00
- MLP $11,273,000.00
- Revenue This Year
- FHTX N/A
- MLP N/A
- Revenue Next Year
- FHTX $15.40
- MLP N/A
- P/E Ratio
- FHTX N/A
- MLP N/A
- Revenue Growth
- FHTX N/A
- MLP 18.71
- 52 Week Low
- FHTX $2.70
- MLP $13.76
- 52 Week High
- FHTX $10.25
- MLP $26.46
- Technical
- Relative Strength Index (RSI)
- FHTX 61.38
- MLP 68.49
- Support Level
- FHTX $7.95
- MLP $21.29
- Resistance Level
- FHTX $9.54
- MLP $22.70
- Average True Range (ATR)
- FHTX 0.56
- MLP 1.08
- MACD
- FHTX 0.19
- MLP 0.23
- Stochastic Oscillator
- FHTX 82.08
- MLP 95.35
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About MLP Maui Land & Pineapple Company Inc.
Maui Land & Pineapple Co Inc is a landholding and operating company. ML&P owns, develops, sells, and manages residential, resort, commercial, agricultural, and industrial real estate. It operates in three segments: Land Development & Sales: , which includes land planning and entitlement, development, and sales activities.; Leasing operations include residential, resort, commercial, agricultural, industrial land and property leases; and Resort Amenities segment, which include a membership program that provides certain benefits and privileges within the Kapalua Resort for its members. The majority of its revenue is derived from the Leasing segment. Leasing revenue is generated from restaurants, retail outlets, office buildings, warehouses, and other resort activities.